JP2025510911A5 - - Google Patents

Info

Publication number
JP2025510911A5
JP2025510911A5 JP2024557189A JP2024557189A JP2025510911A5 JP 2025510911 A5 JP2025510911 A5 JP 2025510911A5 JP 2024557189 A JP2024557189 A JP 2024557189A JP 2024557189 A JP2024557189 A JP 2024557189A JP 2025510911 A5 JP2025510911 A5 JP 2025510911A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
dmt
meo
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024557189A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510911A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/057883 external-priority patent/WO2023186835A1/en
Publication of JP2025510911A publication Critical patent/JP2025510911A/ja
Publication of JP2025510911A5 publication Critical patent/JP2025510911A5/ja
Pending legal-status Critical Current

Links

JP2024557189A 2022-03-27 2023-03-27 精神障害の治療 Pending JP2025510911A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP22000086 2022-03-27
EP22000083 2022-03-27
EP22000083.0 2022-03-27
EP22000086.3 2022-03-27
EP23153995.8 2023-01-30
EP23153939.6 2023-01-30
EP23153995 2023-01-30
EP23153939 2023-01-30
PCT/EP2023/057883 WO2023186835A1 (en) 2022-03-27 2023-03-27 Treatment of mental disorders

Publications (2)

Publication Number Publication Date
JP2025510911A JP2025510911A (ja) 2025-04-15
JP2025510911A5 true JP2025510911A5 (cg-RX-API-DMAC7.html) 2026-04-08

Family

ID=93292079

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024557189A Pending JP2025510911A (ja) 2022-03-27 2023-03-27 精神障害の治療

Country Status (7)

Country Link
US (1) US20250241894A1 (cg-RX-API-DMAC7.html)
EP (1) EP4499086A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025510911A (cg-RX-API-DMAC7.html)
KR (1) KR20250005172A (cg-RX-API-DMAC7.html)
AU (1) AU2023246680A1 (cg-RX-API-DMAC7.html)
CA (1) CA3255635A1 (cg-RX-API-DMAC7.html)
IL (1) IL315890A (cg-RX-API-DMAC7.html)

Similar Documents

Publication Publication Date Title
JP2025510914A5 (cg-RX-API-DMAC7.html)
JP2025511081A5 (cg-RX-API-DMAC7.html)
JP2025511084A5 (cg-RX-API-DMAC7.html)
JP2025510912A5 (cg-RX-API-DMAC7.html)
JP2025510368A5 (cg-RX-API-DMAC7.html)
JP2025510916A5 (cg-RX-API-DMAC7.html)
JP2025510369A5 (cg-RX-API-DMAC7.html)
JP2025510295A5 (cg-RX-API-DMAC7.html)
JP2025512831A5 (cg-RX-API-DMAC7.html)
CA3255348A1 (en) 5-METHOXY-N,N-DIMETHYLTRYPTAMINE FOR THE TREATMENT OF PSYCHOMOTOR SLOWING
Sălcudean et al. The efficacy of antidepresive treatment on COVID-19 pandemic-related depressive symptoms-A prospective, single-center, questionnaire-based study
Sinha et al. Immediate respiratory management of the preterm infant
Bassetti et al. Poststroke hypersomnia
Gasmi et al. Sleep, dietary melatonin supplementation, and COVID-19
Hussein Sr et al. Anxiolytic and sedative properties of melatonin premedication in pediatrics undergoing elective cardiac catheterization: a randomized placebo study
MX2007001822A (es) Uso de xenon como neuroprotector en un individuo neonatal.
Bach et al. The effect of surgically assisted rapid maxillary expansion on sleep architecture: an exploratory risk study in healthy young adults
Lamas-Aguilar et al. Armodafinil as a Potential Pharmacological Treatment for Attention Deficit Hyperactivity Disorder in Adults: A Review
JP2019504040A (ja) 中等度〜重度のインフルエンザの処置
Pasternak et al. An infant with chronic, relapsing polyneuropathy responsive to steroids
Mogavero et al. Psychophysiology of Sleep
JP2025511072A5 (cg-RX-API-DMAC7.html)
Kamal Link of COVID-19 and neurodegenerative disorders
Cummins et al. Belladonna poisoning as a facet of psychodelia
Bozorgipour COVID-19 infection, Implications, Complications, and Challenges